<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044234</url>
  </required_header>
  <id_info>
    <org_study_id>M18-816</org_study_id>
    <nct_id>NCT05044234</nct_id>
  </id_info>
  <brief_title>A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects With Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic disease characterized by marked inflammation and thickening of the&#xD;
      skin that results in thick, scaly skin plaques. This study will assess how safe and effective&#xD;
      cedirogant (ABBV-157) is compared to placebo in adult participants with moderate to severe&#xD;
      psoriasis. Efficacy and safety-related measurements are assessing disease activity in&#xD;
      participants with plaque psoriasis.&#xD;
&#xD;
      Cedirogant (ABBV-157) is an investigational drug being developed for the treatment of chronic&#xD;
      plaque psoriasis. Participants will be put into 1 of 4 groups, called treatment arms and each&#xD;
      group receives a different treatment. There is a 1 in 4 chance that participants will be&#xD;
      assigned to placebo. Approximately 200 adult participants with moderate to severe plaque&#xD;
      psoriasis will be enrolled at approximately 45 sites.&#xD;
&#xD;
      Participants will receive oral daily doses of cedirogant or placebo capsules for 16 weeks.&#xD;
&#xD;
      There may be a higher burden for participants in this study compared to usual standard of&#xD;
      care. Participants will attend regular visits per routine clinical practice. The effect of&#xD;
      the treatment will be checked by medical assessments, checking for side effects, and&#xD;
      questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">March 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving &gt;=75% Reduction from Baseline in Psoriasis Area Severity Index (PASI) score (PASI 75)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI is a tool that provides a numeric scoring for participants' overall psoriasis disease state, ranging from 0 to 72, with a higher score indicating more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear</measure>
    <time_frame>Week 16</time_frame>
    <description>The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &gt;=50% Reduction from Baseline in PASI Score (PASI 50)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI is a tool that provides a numeric scoring for participants' overall psoriasis disease state, ranging from 0 to 72, with a higher score indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &gt;=90% Reduction from Baseline in PASI Score (PASI 90)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI is a tool that provides a numeric scoring for participants' overall psoriasis disease state, ranging from 0 to 72, with a higher score indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 100% Reduction from Baseline in PASI Score (PASI 100)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI is a tool that provides a numeric scoring for participants' overall psoriasis disease state, ranging from 0 to 72, with a higher score indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Symptoms Scale (PSS) Total Score of 0 for Participants with PSS &gt;0 at Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>The PSS is a 4-item patient-reported outcome instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an Itch Numerical Rating Scale (NRS) &gt;=4-Point Improvement from Baseline for Participants with Itch NRS &gt;=4 at Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>The Itch NRS is an 11-point scale that participants complete daily to describe the intensity of their itch using a 24-hour recall period. Scores vary between 0, representing &quot;no itching&quot; and 10, representing &quot;worst itch imaginable.&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Cedirogant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cedirogant Dose A once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Cedirogant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cedirogant Dose B once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Cedirogant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cedirogant Dose C once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cedirogant</intervention_name>
    <description>Capsule, Oral</description>
    <arm_group_label>Arm 1: Cedirogant</arm_group_label>
    <arm_group_label>Arm 2: Cedirogant</arm_group_label>
    <arm_group_label>Arm 3: Cedirogant</arm_group_label>
    <other_name>ABBV-157</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, Oral</description>
    <arm_group_label>Arm 4: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Participants with stable moderate to severe plaque psoriasis of at least 6 months&#xD;
        duration and who are candidates for systemic therapy or phototherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary non-responders to previous anti-IL-17 (e.g., secukinumab, ixekizumab,&#xD;
             brodalumab), anti-IL-23 (e.g., guselkumab, tildrakizumab, risankizumab), or&#xD;
             anti-IL-12/23 (e.g., ustekinumab) treatment for chronic plaque psoriasis.&#xD;
&#xD;
          -  Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis,&#xD;
             medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis&#xD;
             or any other skin disease which may interfere with assessment of chronic plaque&#xD;
             psoriasis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB Department of Dermatology /ID# 238563</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research /ID# 239536</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medderm Associates /ID# 238834</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakes Research, LLC /ID# 238831</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenus Research &amp; Medical Group /ID# 238695</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida, Inc. /ID# 238709</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 238856</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Dermatology Clinical Research /ID# 238679</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060-1047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology /ID# 238701</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin, LLC /ID# 238704</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 239250</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC /ID# 238514</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group /ID# 238708</name>
      <address>
        <city>Kew Gardens</city>
        <state>New York</state>
        <zip>11415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai /ID# 238942</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Medical Group /ID# 239068</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darst Dermatology /ID# 238677</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Service /ID# 238678</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologists of Southwest Ohio, Inc /ID# 238939</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040-4520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center /ID# 238823</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas /ID# 238827</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts /ID# 238510</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center /ID# 238682</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215-2885</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orion Clinical Research /ID# 238619</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759-4100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research /ID# 238565</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Spokane /ID# 238809</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research /ID# 238507</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia Research /ID# 238517</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505-0589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Cedirogant</keyword>
  <keyword>ABBV-157</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

